{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018276","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.533414+00:00","generated_at":"2026-06-08T08:48:08.430929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated","bullets":["Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).","Net loss $11.3M vs $6.4M loss in Q3 2022; EBITDA loss $12.9M vs $7.1M.","Cell therapy revenue $4.7M (-40%); drug discovery $1.9M (-5%).","FY2023 guidance reaffirmed: total $34-36M, core $28-30M, SPL ~$6M.","Cash & investments $208.7M; expect ~$200M year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018276","json":"https://secwatch.observer/filing/0001558370-23-018276.json","markdown":"https://secwatch.observer/filing/0001558370-23-018276.md","text":"https://secwatch.observer/filing/0001558370-23-018276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/0001558370-23-018276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/mxct-20231108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:48:08.430929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2687edb8435e641b6a59c029c14b129e58865512","claim":"MAXCYTE, INC. reported the third quarter ended September 30, 2023 results: revenue Total revenue of $8.0 million in the third quarter of 2023, net income Third quarter 2023 net loss was $11.3 million. Guidance reaffirmed.","evidence_excerpt":"MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications , today announced financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023018276/0001558370-23-018276-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"Total revenue of $8.0 million in the third quarter of 2023"},{"label":"Net income","value":"Third quarter 2023 net loss was $11.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}